PET CANCER THERAPEUTICS MARKET ANALYSIS

Pet Cancer Therapeutics Market – Efficient Cancer Cure in Companion Animals

Pet cancer therapeutics are the novel drug molecules that exhibit high potential to reduce the effects of cancer, giving access to comprehensive cancer care with minimum side effects. Cancer therapies aims to permanently eradicate the cancerous cells prevalent in pets. The veterinarian recommends specific treatment program such as targeted therapy and combination therapy or chemotherapy depending on the type of cancer, stage, and nature of the cancer. The ongoing research activities undertaken by the scientists for the development of novel formulations and therapies is expected to accelerate the market growth. For instance, the scientists at University of Veterinary Medicine are currently exploring the molecular basis of cancer progression in canine cell lines, stating that the modern cancer therapy can be revolutionized with the introduction of targeted therapies.

The global pet cancer therapeutics market was valued at US$ 183.3 million in 2017 and is expected to witness a robust CAGR of 7.7% over the forecast period (2017 - 2025).

Figure 1. Global Pet Cancer Therapeutics Market (US$ Mn), by Region, 2017

To learn more about this report, Request sample copy

Source: Coherent Market Insights (2018)

Increasing R&D initiatives for cancer management to augment market growth

Increasing number of research grants to launch various anti-cancer therapies for veterinary cancer treatment is expected to be a major factor driving growth of the global pet cancer therapeutics market in near future. For instance, in 2017, Animal Cancer Foundation (ACF) received a US$ 1 million grant from the Blue Buffalo Foundation to support comparative oncology research, which aimed to study similarities between naturally occurring cancers in people and pets and find effective treatment in both species. Also, in 2016, the Petco Foundation and Blue Buffalo Foundation invested US$ 2.35 million to support pet cancer research and treatment, as it represents a major cause of illness and premature death in affected species worldwide. Moreover, in 2017, Jackson Laboratory launched Tallwood Canine Cancer Research Initiative (TCCRI), to create a biobank of dog tumors for providing insights on cancer cure through research, in order to develop the most effective cancer therapy. Furthermore, organizations such as Animal Cancer Foundation, Petco Foundation, Veterinary Cancer Society, and PetCure Oncology are conducting oncology research such as canine cancer genome project to understand the genetic makeup of cancer tumors in animals, in order to discover targeted drug therapies with least toxic doses. However, increasing adoption of alternative treatment methods such as herbal medications, homeopathy and adverse effects such as diarrhea, musculoskeletal disorder, anorexia and high cost associated with pet cancer treatment are the factors restraining the market growth.

Increasing incidence and remission rates of pet cancers to accelerate the market growth

Increasing prevalence of cancer indicates a need to adopt approved novel therapies, which are proved to be highly effective for the treatment of cancers in pets, thus, augmenting the pet cancer therapeutics market growth during the forecast period. According to the study by Fetch a Cure, 2015, dogs and cats have a higher incidence of tumors than humans, where dogs are 35 times more likely to develop skin cancer, 4 times more likely to develop breast tumors, and 8 times more likely to develop bone cancer. According to the study published by Animal Cancer Foundation, 2017, approximately around 25% of all dogs will develop a tumor at some point in their life. Furthermore, increasing number of relapsed cancer rates and the availability of relapsed/ refractory therapeutics integrated with veterinarian recommendation is expected to additionally generate the revenue for the market players. According to the study by petMD, LLC, 2015, about 95% of dogs treated for lymphoma with chemotherapy protocols and conventional treatments are expected to experience disease relapse or remission. The duration of remission is less than 15 months in 50% of dog species. In 2017, a novel chemotherapy drug named Tanovea-CA1 (rabacfosadine for injection), manufactured by VedDC, Inc. was conditionally approved by the FDA as a first line treatment for dogs to treat relapsed/refractory lymphoma and canine lymphoma. The conditional approval of drug allows manufacturer to legally sell Tanovea-CA1, before proving it meets the substantial evidence standard of effectiveness for full approval.

The major players operating the global pet cancer therapeutics market include Aratana Therapeutics, Inc., AB Science, Boehinger Ingelheim International GmbH, Zenoaq, Morphogenesis, Inc., VetDC, Inc., Karyopharm Therapeutics, Inc., Regeneus Ltd., Rhizen Pharmaceuticals SA, Oasmia Pharmaceuticals AB, and Zoetis.